Accutar Biotechnology
PrivateLast Round
Series C
Apr 7, 2021
Total Funding Raised
$63.15M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Accutar Biotechnology is a clinical-stage biotechnology company that utilizes an artificial intelligence-empowered platform for drug discovery and development.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Accutar Biotechnology Comparables
Compare Accutar Biotechnology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SEED Therapeutics | 84% | |
| Celeris Therapeutics | 84% | |
| Genesis Molecular AI | 84% |
Accutar Biotechnology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Apr 7, 2021 | ||||
| Early Funding | Dec 21, 2020 | ||||
| Series B | Dec 21, 2020 | ||||
| Early Funding | Aug 12, 2019 | ||||
| Series A | Jan 10, 2018 | ||||
Series A | Dec 5, 2017 |
Accutar Biotechnology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CDH Investments | Early Funding, Series C, Series B |
| IDG Capital | Series C, Series A |
| ZhenFund | Seed |
| Primavera Capital Group | Early Funding, Series C |
| Primavera Venture Partners | Series B |
| Yunfeng Capital | Series C |
| CDH Investments | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 99% MoM.
- Jul 25, 2026
Monthly visitors grew 299% MoM, reaching 1.1K.
Accutar Biotechnology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Accutar Biotechnology's valuation, stock price, and market status.
Is Accutar Biotech a public or private company?
Accutar Biotech is a private company.
What is the current stock price of Accutar Biotech?
Accutar Biotech is a private company with no public stock price. No recent secondary market data is available.
How much is Accutar Biotech worth (valuation)?
Valuation information for Accutar Biotech is not publicly available.
Can I buy Accutar Biotech stock?
Accutar Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Accutar Biotech's last funding round?
Accutar Biotech's most recent funding round was Series C on April 18, 2021.
Who are the main investors in Accutar Biotech?
Key investors in Accutar Biotech include CDH Investments, IDG Capital, Yunfeng Capital, 3W Partners Capital.
Will Accutar Biotech IPO soon?
No public IPO plans have been announced for Accutar Biotech.
How can I track Accutar Biotech secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Accutar Biotech's secondary market activity and sign up for updates.